Nancy Brennan

Feel Like Yourself Again

The most dangerous thing about breast cancer isn't the tumor. It isn't even the chemotherapy. It's the pill they hand you afterward and tell you to take for the next ten years. My name is Nancy Brennan. I have been an oncology nurse for 22 years. What I have learned in 22 years is this. Most of my breast cancer patients in remission never make it through hormone therapy. The pain pushed them off their medication first. I want to be precise about what I mean, because I am not saying this to frighten you. I am saying it because I spent the first decade of my career watching this happen without understanding why. And I have spent the second decade trying to make sure that the patients who come through our unit understand the connection that their care team is almost certainly not explaining to them. The joint pain is not a separate condition from the drug. It is being caused by the same mechanism that is keeping your risk low. And the standard of care has a name for what happens to your joints. Side effects. Two words in a chart note. Two words that close the conversation before it starts. Because the moment something is labeled a side effect, nobody investigates what is actually happening. Nobody explains the mechanism. Nobody treats it at the root. They manage the risk and they hand you the same pain advice they would give a sixty-year-old with arthritis, and those are not the same thing. That disconnect is what I have watched take patients from me. Let me tell you about the ones I think about most. The first is a woman I will call Diane. Fifty-seven when she started anastrozole. ER+, Stage 2, caught early. Lumpectomy, four rounds of TC, twenty sessions of radiation. By the time she sat in front of her oncologist for the hormone therapy conversation, she had already survived the part she thought would be the hardest. The stiffness started around month four. Knees first. A tightness when she stood up from a chair that had not been there before. Then her hips. A dull ache after walking that built through the afternoon and settled into her lower back by evening. Her oncologist noted it in the chart. Common side effects. She was prescribed Celebrex just to get through the mornings. By year two, she stopped going on her walks. She stopped kneeling in her garden. She stopped carrying her own groceries from the car. She rearranged her kitchen so everything she needed was at counter height because reaching up and bending down had both become decisions she had to make with her body's permission. By year four, she was using a cane inside her own house. Her knees had deteriorated to the point where the orthopedic surgeon told her both needed replacing. She was sixty years old. He told her the cartilage damage was consistent with what he typically saw in patients fifteen to twenty years older. She had the first knee replaced that fall. She spent her sixty-first birthday in a rehabilitation facility, learning to walk on a joint she would not have needed if anyone had addressed what four years of the drug had done to her cartilage. She never missed a dose. She did everything right. The drug worked. Her joints paid for it. I remember going through her chart after the surgery referral came through. Four years of notes. Side effects documented at every visit. Not once, in four years, had anyone explained to her what was actually happening inside her joints at the mechanical level. Not once had anyone treated the underlying process. The chart said side effects, and the conversation ended there, every time, for four years, while her knees deteriorated to the point of surgical replacement. The second patient I think about is a woman I will call Ruth. Sixty-three. ER+, diagnosed four years earlier. Lumpectomy and radiation. No chemotherapy. Her oncologist started her on letrozole the month after radiation ended. The joint pain began within the first six months. By the end of the first year she was waking up every morning with her fingers so stiff she could not close them around a glass of water. She described it to me at one of her visits as feeling like her hands had aged thirty years overnight. Her oncologist switched her to exemestane. There was a brief window where things felt different. Then the same pain returned in the same joints, building the same way it had before. Ruth did not come to her follow-up appointment. I did not see her for eleven months. Then her name appeared on a different chart. Different floor. Different reason. The cancer had returned. Same breast bed. It had metastasized to her bones. Ruth told the oncology team she had stopped taking the exemestane fourteen months earlier. The pain had become unbearable and she could not get anyone to explain why it was happening or to offer her anything beyond switching to another version of the same drug she had already tried. Ruth died nine months later. I stood in the hallway after I read her chart and I could not move for a full minute. I had sat across from that woman in an exam room. I had taken her vitals. I had watched her wince when she stood up from the chair. And the only thing the system had offered her was a different brand name for the same mechanism that was destroying her joints. She did not quit because she was weak. She quit because the pain had become unmanageable and nobody gave her a third option. There is a third patient I want to tell you about, because she is the one who finally made me understand what I was watching. Her name was Kathleen. Fifty-eight. On aromatase inhibitors for two and a half years. She had switched medications twice. She had tried supplements, and they had done nothing she could feel. Her oncologist had flagged turmeric as potentially estrogenic, so she stopped that after a month. She was taking a prescription anti-inflammatory daily and it was barely keeping her functional. She was the patient who did everything she was told. What Kathleen did not know, because nobody had explained it to her, is that the pattern of joint deterioration she was experiencing — bilateral, symmetrical, concentrated in the hands, knees, and weight-bearing joints — was not consistent with age-related wear. It was consistent with a systemic inflammatory response triggered by hormonal withdrawal. Her inflammatory markers, the ones that would have shown exactly what was driving the damage, were not on any panel her oncologist reviewed. Kathleen came back for her follow-up eight months later. The first thing she said to me when I walked into the exam room was: Why has nobody told me what this drug is actually doing to my joints. I did not have a good answer for her. What I had was a system in which the drug's benefit had been explained to her in full clinical detail and the drug's cost had been explained in two words. I have stopped counting how many versions of Diane and Ruth and Kathleen I have seen in 22 years. What I have not stopped thinking about is why. Why the same drug, in the same patients, with the same joint pain, always ends one of two ways. The body deteriorates around it. Or the patient stops taking it and the cancer comes back. I have watched both paths for most of my career. What I could never stop asking was why there had never been a third. Here is what most doctors treating breast cancer patients on aromatase inhibitors are not explaining clearly enough. Every joint in the body accumulates chronic, low-grade inflammation over a lifetime. Mechanical stress from daily movement, gradual cartilage wear, normal cellular aging. This produces a baseline level of inflammatory activity that runs in every joint continuously. In a healthy body, this baseline remains low enough that the body manages it without producing symptoms. You do not feel it. You do not know it is there. The reason you do not feel it is estrogen. Estrogen plays a regulatory role in joint health that most patients are never told about. It maintains the production of synovial fluid, the viscous liquid that lubricates the space between bones and allows them to move against each other without friction. It suppresses inflammatory cytokines, specifically interleukin-6 and tumor necrosis factor-alpha, the signaling molecules that drive the inflammatory cascade in joint tissue. It supports cartilage integrity by regulating the balance between cartilage-building cells and cartilage-degrading enzymes. Your joints were never fine on their own. Estrogen was performing a continuous regulatory function that kept the baseline inflammation stable, the cartilage protected, and the synovial fluid at the viscosity your joints required to move without pain. The entire purpose of an aromatase inhibitor is to suppress estrogen production. That is how the drug reduces the risk of recurrence. It removes the hormone the cancer cells depend on. And it works. But the day the estrogen drops, the inflammatory activity it was regulating begins to climb. It does not climb all at once. It builds gradually. Week after week. Month after month. Interleukin-6 levels rise. Tumor necrosis factor-alpha increases. The inflammatory signaling that estrogen had been keeping in check intensifies across every joint simultaneously. Synovial fluid production decreases. The lubricant between the bones thins. Cartilage that was being maintained by estrogen-dependent processes begins to degrade faster than the body can repair it. The tendons that were flexible under estrogenic regulation begin to stiffen and thicken. The morning stiffness is not just a side effect. It is the physical consequence of joints operating without the regulatory hormone they were built to rely on. The body does not adapt to this. The longer estrogen remains suppressed, the more inflammatory activity accumulates. The cartilage degradation continues. The synovial fluid continues to thin. This is why switching from anastrozole to letrozole to exemestane produces the same result in most patients. The three drugs differ in their chemical structure. They do not differ in their mechanism. All three suppress aromatase. All three lower estrogen. All three remove the same regulatory function from the same joints. The brief window of reduced pain after a switch is the residual inflammation from the previous drug clearing before the new drug's identical mechanism rebuilds it. The clinical term is aromatase-inhibitor-associated musculoskeletal syndrome. Up to 50% of women on aromatase inhibitors experience it. It is the single most common reason women discontinue the drug that is keeping their cancer from returning. The joint pain is not a footnote in the treatment protocol. It is the primary threat to treatment compliance. And the current standard of care does not treat it at the root. That statistic changed how I practice. Because what it told me was that the greatest risk to my patients was not the cancer recurring on its own. It was the pain driving them off the drug that was preventing the recurrence. Ruth did not die because her cancer was aggressive. She died because her joint pain was unmanageable and nobody addressed what was causing it. Diane's knees did not fail because she was old. She was fifty-seven. They failed because four years of unregulated inflammatory activity degraded her cartilage to a point that required surgical replacement. The orthopedic surgeon documented damage consistent with a patient two decades older. That was not aging. That was a predictable consequence of estrogen suppression in the absence of any intervention to manage the inflammatory cascade the drug set in motion. Now I want to tell you what every approach these women tried was and was not doing. Switching aromatase inhibitors. Same drug class. Same estrogen suppression. Same mechanism. The hope that a different brand will produce different joint outcomes is not supported by the pharmacology. Anastrozole, letrozole, and exemestane all suppress aromatase. The brief relief some patients feel after switching is the old inflammatory buildup clearing before the new drug's identical mechanism generates the same buildup again. The mechanism has not changed. Only the timeline has reset. NSAIDs. Ibuprofen, naproxen, Celebrex, meloxicam. They reduce pain signaling. They do not address the upstream cause, which is the absence of estrogen's regulatory function over the inflammatory cascade. They manage the symptom. The process driving the symptom continues behind the managed pain. And daily NSAID use over the multi-year timeline of hormone therapy carries gastrointestinal and cardiovascular risks that compound with every year of continuous use. Claritin. An antihistamine designed for allergic response. Some oncologists recommend it for aromatase-inhibitor-associated joint pain. The mechanism by which loratadine might affect musculoskeletal symptoms is not well established. For most women, the relief is modest at best, and it does nothing to address the underlying inflammatory process driving the cartilage and synovial degradation. Turmeric. Multiple oncologists flag curcumin as potentially estrogenic. A woman on an aromatase inhibitor cannot afford a supplement that might interfere with the drug keeping her risk low. Kathleen's oncologist pulled her off it within a month. Each one manages around the problem. None of them address the inflammation at its source without interfering with the estrogen suppression the drug is designed to maintain. About three years ago, I started seeing something I could not explain inside that framework. A cluster of patients in our unit whose joint symptoms were not following the trajectory I expected. Women who had been on aromatase inhibitors for years, who had already cycled through all three medications, who had already done the month-long break and restarted, who had been living on daily NSAIDs just to function. These women were walking into their follow-up appointments differently. I do not mean they told me they felt better. I mean I could see it. When you spend twenty years in an exam room with patients on aromatase inhibitors, you learn what the joint pain looks like from the inside of a clinic. The way a woman braces on the armrest before she stands from the patient chair. The slow, measured steps from the waiting room. The way her fingers fumble the snap on her purse or struggle to roll up a sleeve for the blood pressure cuff. You see it before anyone says a word. What I started noticing was the absence of those things. A patient who had been bracing on the armrest for three consecutive visits stood up in one motion without pausing. Her fingers worked the clasp on her bag without hesitation. She walked from the chair to the exam table at a pace that did not match what I had seen from her six months earlier. The first thing I asked every patient was whether she had stopped her medication. They had not. Still taking it. Every morning. I started pulling charts. Looking for what had been introduced. A new prescription. A new referral. A procedure I had not been informed of. I found nothing in the clinical record. So I started asking each of them directly, at the end of their follow-up visits, what was different in their routine. Every one of them named the same thing. A supplement. Tart cherry. Senaria. I pulled the research. A clinical trial published in Supportive Care in Cancer documented measurable reductions in inflammatory markers, including C-reactive protein and interleukin-6, in women on aromatase inhibitors taking a standardized tart cherry extract. A systematic review across multiple randomized controlled trials confirmed the anti-inflammatory effect across several biomarkers linked to hormone-therapy-associated joint deterioration. Not a single study funded by a supplement company. Peer-reviewed research in major journals. The mechanism is documented. Tart cherry contains a class of compounds called anthocyanins, the deep red pigment concentrated in the skin of the fruit. Anthocyanins inhibit the COX-2 and NF-kB inflammatory pathways. These are the same pathways that escalate when estrogen is suppressed by an aromatase inhibitor. They reduce interleukin-6 and C-reactive protein, the same inflammatory markers that climb in women on hormone therapy. They go directly to the inflammatory cascade and reverse it at the signaling level. Anthocyanins have no estrogenic activity. They do not bind to estrogen receptors. They do not stimulate estrogen production. They do not inhibit or interfere with the aromatase enzyme. The aromatase inhibitor continues functioning exactly as prescribed. Estrogen levels remain exactly where the oncologist wants them. The inflammation subsides. Estrogen stays exactly where the medication put it. That is the third path. The one that did not exist in the protocol. Stay on the drug. Address the inflammation it leaves behind. Keep both. The reason your care team has not mentioned this is not because the research is absent. It is because there is no pharmaceutical company distributing it and no prescription to write. There is no specialist whose training included it. There is no pharmaceutical rep walking into the oncology office explaining the trial data. The research exists. The pipeline to deliver it to your doctor does not. The brand my patients were using is Senaria. I looked carefully at what makes it different from what lines most pharmacy and supplement shelves, because the difference matters more than most people realize. Most tart cherry supplements on the market use modern commercial cherry varieties, cheaper to source, widely available. These varieties have been selectively bred for sugar content and shipping durability for over a century. Every generation bred for sweetness reduced the anthocyanin concentration in the fruit. The label says tart cherry. It is tart cherry. But the compound that made it medicinal has been diluted to a fraction of what the original fruit contained. Senaria uses Montmorency, an heirloom variety, never hybridized, with anthocyanin concentrations ten to twenty times what modern commercial cherries contain. Not just labeled Montmorency. Tested and verified at the variety level before the capsule is produced. The dose and standardization matter. The research documented results using a tart cherry extract standardized for its anthocyanin content, at a clinically relevant dose. Most products on pharmacy shelves and online contain unstandardized powder at doses well below what the clinical literature evaluated. Senaria delivers 3,600 milligrams per serving of a standardized extract, verified for anthocyanin concentration before encapsulation. Two capsules. That is the full protocol. The processing matters. Anthocyanins are heat-sensitive compounds. They begin to degrade at temperatures above 200 degrees. Most tart cherry supplements are manufactured using high-temperature spray-drying, which is cheaper, faster, and destroys a significant portion of the anthocyanin content before the capsule is sealed. What reaches the consumer is a red-colored powder with a fraction of the active compound remaining. Senaria is cold processed. The anthocyanins are intact when the capsule reaches your body. Senaria is not sold on Amazon, Walmart, or through any third-party marketplace. If you are looking at tart cherry supplements on those platforms, there is no reliable way to verify the variety, the anthocyanin standardization, or the processing method. The patients of mine who have seen results purchased directly from the Senaria website, where the sourcing, testing, and formulation can be confirmed. What I observe consistently in the patients who stay with the full protocol: The mornings shift first, within the first two weeks. Not dramatically. But the time between standing up and moving normally shortens. The warm-up period that had been running twenty or thirty minutes compresses. They notice they walked to the bathroom in the middle of the night without bracing on the wall. They report this before anything else changes. The mornings are where the difference shows up first. By week three to four, the hands start cooperating. They can grip a coffee cup without thinking about it. They can button a shirt without the usual negotiation with their fingers. One patient told me she opened a water bottle for the first time in months and did not realize what she had done until it was already open. The fine motor tasks that had required conscious effort start becoming automatic again. By week six to eight, the walking changes. They go to the mailbox without planning the route around their pain. They stand up from a chair in one motion. Their spouse mentions it before they do. The movements that had required conscious planning begin happening the way they used to happen, without thought, without bracing, without the mental calculation of whether the pain is worth the task. At the three-month mark, the full picture becomes visible. They feel like their age. Not thirty years older. They can get on the floor with grandchildren and get back up without help. They can climb stairs without gripping the railing with both hands. They sit through a dinner with friends and stand up at the end without the stiffness that used to make them dread the moment. They describe it in the same words, nearly every time. I feel like myself again. I have one patient I want to close with. A woman I will call Judith. Sixty-one. Two years post-treatment. On anastrozole for eighteen months when I first saw her. She had already switched from letrozole after the first year. She was taking daily naproxen and wearing compression gloves to bed. Her knees ached after any walk longer than ten minutes. Her fingers swelled overnight and took most of the morning to loosen. She had stopped accepting invitations from friends because she could not predict whether her body would cooperate on any given day. She started Senaria after a follow-up visit where she told me she was considering stopping the anastrozole entirely. The pain had reached the point where she was weighing the risk of recurrence against the certainty of what the drug was doing to her body every day. She was standing in the same place Ruth had stood. I could see it. At her next appointment, I noticed her before I reached the exam room. She walked in from the waiting room without the measured, careful steps I had seen from her at every prior visit. She sat down in the patient chair, realized her bag was on the wrong side, stood back up to move it, and sat down again. One continuous motion. No pause. No bracing. When I asked her what had changed, she said: my hands work in the morning. I walked my neighborhood loop last week for the first time since I started the medication. I got down on the floor with my grandson on Saturday and got back up without help. I am sleeping through the night. Her oncologist noted improved compliance at the same visit. She had stopped skipping doses. I cannot promise Judith's result to every person who reads this. What I can tell you is that what I watched happen in her body is consistent with what happens when the inflammatory cascade is finally addressed directly, without disrupting the estrogen suppression the drug is designed to maintain. Three months is where the full result shows up. The patients who committed to three months are the ones I have watched see meaningful, measurable change. The patients who tried two or three weeks and stopped are the ones I cannot evaluate clearly, because the mechanism does not produce its full result on a short timeline. That is why Senaria structures the three-month supply as the primary option. One bottle is thirty servings, thirty days. Three bottles is ninety days, the full cycle consistent with what the research documented. If you are going to find out whether this addresses the inflammation your medication leaves behind, three months is the honest test. If you are concerned it may not work for you, Senaria backs every purchase with a 90-day money-back guarantee. Full refund. No questions asked. If you do not feel a meaningful difference in ninety days, you send back what is left and every dollar is returned. There is no financial risk in finding out. If you are on an aromatase inhibitor and the joint pain is building with each passing month, and you have already switched medications and tried what your doctor suggested and you are still waking up every morning calculating how much pain today will cost you, you are where Diane and Ruth and Kathleen were. At the stage where the window is still open. The medication is doing its job. It is keeping your estrogen where it needs to be to keep your risk low. Nobody is addressing what happens to your joints when the estrogen drops. That is the third path. The one your care team should be offering you. They are not offering it. So I am. ~ Nancy Brennan, Oncology Nurse, 22 years